Thalassemia
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
Subtype terms (3)
More specific conditions that are subtypes of Thalassemia in the MeSH hierarchy.
- alpha-Thalassemia
5 drugs (1 approved, 4 experimental)
- beta-Thalassemia
126 drugs (64 approved, 62 experimental)
- delta-Thalassemia
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 3 trials (11)
Phase 2 trials (23)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (39)
- Gilead Sciences
- Novartis
- University of Arizona
- Baqiyatallah Medical Sciences University
- Azienda Ospedaliera V. Cervello
- Cairo University
- University of London
- Cornell University
- Harvard University
- Guangxi Medical University
- Hacettepe University
- Hainan People's Hospital
- Nanjing University
- Ospedale Microcitemico
- Tanta University
- University of Tehran
- University of Athens
- Fujian Medical University
- Peking University
- Xiamen University
- University of Cagliari
- University of California, San Francisco
- University of Tabriz
- University of Indonesia
- Jiao Tong University
- American University of Beirut
- Guangzhou University
- University of Turin
- Iranian Blood Transfusion Research Center
- Tabriz Medical University
- +9 more
Organization Involved with Phase 3 Indications (24)
- Acceleron Pharma, Inc.
- Emmaus Medical
- Celgene
- Cerus Corporation
- Hamad Medical Corporation
- Madaus Inc
- bluebird bio
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Pennsylvania
- Ain Shams University
- Ege University
- New England Research Institutes
- University of Toronto
- Aga Khan University
- University of Campinas
- University of Minnesota
- Beni Suef University
- Isfahan University
- Ospedale Regionale per le Microcitemie azienda
- The University of Texas, Dallas
- Maternity and Children Hospital, Makkah
Organization Involved with Phase 2 Indications (95)
- Imara, Inc.
- Shire
- Vertex
- Roche
- Genzyme
- Bellicum Pharmaceuticals
- Bioverativ Therapeutics Inc.
- EmeraMed
- GlaxoSmithKline
- Ionis Pharmaceuticals, Inc.
- La Jolla Pharmaceutical Company
- Nova Laboratories Limited
- Protagonist Therapeutics
- Sponsor GmbH
- Vifor Inc.
- Agios Pharmaceuticals, Inc.
- Gamida Cell
- Fondazione Telethon
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Roma La Sapienza
- Laikο General Hospital, Athens
- University of Pittsburgh
- Central South University
- Baylor University
- Blood Center of Wisconsin
- Boston University
- Case Western Reserve University
- +65 more
Organization Involved with Phase 1 Indications (13)
- FerroKin BioSciences
- Invenux, LLC
- Prolong Pharmaceuticals
- Silence Therapeutics GmbH
- Sideris Pharmaceuticals
- Guangzhou University of Traditional Chinese Medicine
- BGI Group
- City of Hope National Medical Center
- State University of New York, Brooklyn
- Kings County Medical Center
- California Institute for Regenerative Medicine
- Shenzhen University
- IQVIA
Organization Involved with Other Experimental Indications (12)
- George Papanicolaou Hospital
- University of Washington
- Guangzhou Medical University
- Hormozgan University of Medical Sciences
- Shenzhen Geno-Immune Medical Institute
- Padjadjaran University
- The University of Hong Kong
- Sun Yat-Sen University
- Chiangmai University
- China Medical University
- Government of Indonesia
- Chinese Academy of Medical Sciences